Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EvommuneEVMN -0.11%10 Pretax Margin % is % as of Jun. 2026. GuruFocus rates EVMN with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Evommune ranks worse than 77.78% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Evommune's Pre-Tax Income for the
three
months ended in Jun. 2026 was $-32.25 Mil. Evommune's Revenue for the
three
months ended in Jun. 2026 was $0.00 Mil. Therefore, Evommune's pretax margin for the quarter that ended in Jun. 2026 was %.
The historical rank and industry rank for Evommune's Pretax Margin % or its related term are showing as below:
EVMN'
s Pretax Margin % Range Over the Past 10 Years
Min: -954.4 Med: -681.06 Max: -529.77
Current: -946.68
EVMN's Pretax Margin % is ranked worse than 77.78% of 945
companies
in the Biotechnology industry
Industry Median: -85.15
vs EVMN: -946.68
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Evommune Pretax Margin % Related Terms
Evommune Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Evommune's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVMN vs OCGN, PBYI, LRMR: Pretax Margin % Comparison
For the Biotechnology subindustry, Evommune's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evommune Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evommune's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Evommune's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evommune (EVMN) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Evommune and its competitors. According to the industry distribution chart, Evommune ranks #735 out of 945 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Evommune's Pretax Margin % too high?
Evommune's current Pretax Margin % is %. Based on the distribution chart, Evommune ranks #735 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evommune has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Evommune's Pretax Margin % compare to OCGN and PBYI?
According to the Biotechnology industry distribution chart, Evommune ranks #735 out of 945 companies for Pretax Margin %. This places Evommune in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Evommune and its competitors. Evommune's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evommune stock overvalued right now?
Evommune (EVMN) has a current Pretax Margin % of %. The current Pretax Margin % is %. Evommune's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Evommune (EVMN), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
10GF Score
Get the complete analysis for EVMN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVMN has been successfully added to your 
